SynthesisBMC cancer2021
Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.
Synthesis in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Rethinking secondary immunodeficiency: a cross-domain pathway framework for risk stratification.Frontiers in immunology · 2026Pooled it
- A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab.Exploration of targeted anti-tumor therapy · 2025Pooled it
- Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis.Blood advances · 2024Pooled it
- Daratumumab in newly diagnosed MM - incorporating lessons learnt from CASSIOPEIA, MAIA and beyond.Nature reviews. Clinical oncology · 2022Trial
- Article
- Prediction of ISS and R-ISS Stratification in Newly Diagnosed Multiple Myeloma Using Lumbar Spine MRI Radiomics Model: A Two-Center Multimodal Study.Journal of imaging informatics in medicine · 2026Article
- Practical recommendations for infectious prophylaxis and vaccination in multiple myeloma patients.Frontiers in medicine · 2026Review
- After CAR-T therapy for myeloma: challenge of persistent cytopenias and infections.Haematologica · 2026Article
- Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?Targeted oncology · 2026Review
- Infection incidence, timing, and predictors in newly diagnosed multiple myeloma: a real-world retrospective cohort study.Frontiers in medicine · 2026Article
- Study protocol for developing a patient-reported outcome measure for infection screening in hematological patients with secondary immunodeficiency.BMC cancer · 2025Article
- Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma.Blood advances · 2025Article
- Incidence and Characteristics of Infectious Complications in Multiple Myeloma Patients Treated With Bispecific Antibodies.Journal of Korean medical science · 2025Article
- A real-world study on the impact of infection load on mortality in multiple myeloma patients in Finland.Annals of hematology · 2025Article
- More than meets the eye: Nocardia farcinica, Candida dubliniensis and Aspergillus spp. co-infection in a patient with multiple myeloma treated with multiple treatment regimens.BMC infectious diseases · 2025Article
- Use of Immunoglobulin Replacement Therapy in Clinical Practice: A Review.Journal of immunotherapy and precision oncology · 2025Review
- Gut microbiota in immunomodulation and infection prevention among multiple myeloma patients after chemotherapy: current evidence and clinical prospects.American journal of cancer research · 2025Review
- Clinical analysis of hospital-acquired infections in patients with multiple myeloma: a study of 200 cases.American journal of translational research · 2025Article
- Discontinuation rates, clinical effects and provocation factors of SGLT-2 inhibitor in the real world.Scientific reports · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with multiple myeloma (MM) remain at an increased risk of infection due to the disease process, as well as the ensuing treatments.
methodsWe performed a systematic review to evaluate the monthly risk of grade III/IV infection, pneumonia, and neutropenia in patients with myeloma enrolled in randomized clinical trials (RCTs).
resultsThe risk of grade III or higher infection, pneumonia, and neutropenia persists among all phases of treatment. There was no statistical difference in grade III or higher infection, pneumonia, and neutropenia between frontline and relapsed/refractory setting. In the maintenance setting, the complications of infection, pneumonia, and neutropenia were low, but not negligible. Three-drug regimens were no more likely than two-drug regimens to have an increased risk of Grade III or higher infection.
conclusionsThis is the first study to quantify the monthly risk of grade III or higher infection, pneumonia, and neutropenia across different treatment regimens in the frontline, maintenance, and relapsed/refractory settings. The results of our systematic review demonstrate a significant risk for severe infection, pneumonia, and neutropenia in patients with MM. Further studies are needed to determine the value of antibiotic prophylaxis in a broader myeloma patient population, as well as other approaches that will further mitigate the morbidity and mortality related to infection in this vulnerable patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.